Press release
Researchers from the University of Dundee have discovered a small molecule that helps to eliminate a Parkinson’s disease-causing protein
Press release
Researchers from the University of Dundee have discovered a small molecule that helps to eliminate a Parkinson’s disease-causing protein
Press release
The University of Dundee and Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents, will partner to commercialise technology developed at Dundee that enhances the understanding of undruggable diseases.
Press release
All roads lead west for a University of Dundee scientist who is using pedal power to fund research into Parkinson’s disease.
Press release
University of Dundee spinout Amphista Therapeutics will work with global biopharmaceutical companies as part of strategic collaborations potentially worth more than $2 billion.
Press release
Mutations in PINK1 are the second most frequent cause of autosomal recessive early-onset Parkinson’s disease.
News
Amphista Therapeutics, the spin out company from the lab of Professor Alessio Ciulli, was awarded the ‘Financing Deal of the Year’ award 2021 at the Scrip Awards last month. This was in recognition of their $53M Series B funding.
Press release
Scientists at the University of Dundee and Harvard Medical School have identified the key targets of an enzyme that play a critical role in protecting the brain against the development of Parkinson’s disease.
Press release
A University of Dundee-led programme that will train the next generation of barley researchers has received a multi-million pound investment.
Press release
A University of Dundee researcher is to join an international collaboration that brings scientists from academia together with one of the world’s largest pharma companies to help develop new drugs for cancer and other devastating diseases.
Press release
A novel vaccine production platform that could prove decisive in the battle against Streptococcus is among the University of Dundee innovations recognised in Scotland’s largest company creation programme for the higher education sector.
Press release
A new translational research centre will bolster the University of Dundee’s world-leading position in a field that is revolutionising drug discovery, while helping to facilitate the development of high growth companies and create skilled jobs.
Press release
A near-£1 million investment will help University of Dundee spinout company Ten Bio Ltd to commercialise the human skin culture system it developed to provide a viable alternative for many experiments currently performed on animals.
Press release
Amphista Therapeutics, a University of Dundee spinout company, has announced a near-£40 million investment that will further its work to develop new drugs for a range of diseases.
Press release
Work to build on Dundee’s world-class expertise in biomedical sciences is set to begin in earnest after the ‘Growing the Tay Cities Biomedical Cluster’ project was officially signed off by the Tay Cities Region Joint Committee today (February 19).
Press release
The University of Dundee has welcomed the signing of the Tay Cities Deal, which will boost efforts to capitalise on our world-class strengths in biomedicine and forensic science, creating hundreds of new jobs and attracting further investment.
Press release
A University of Dundee spinout company developing treatments for eczema, rheumatoid arthritis and other inflammatory conditions has completed its first round of private investment.
News
The o2h human health EIS Fund has announced its intention to lead an investment into In4Derm.
Press release
The University of Dundee has been named the best seat of learning in Scotland for supporting spinout businesses, according to new rankings
Press release
Three spinout projects from the University of Dundee with the potential to deliver significant healthcare benefits have received more than £250,000 from Scottish Enterprise to support their development.
Press release
The University of Dundee is to partner with global biopharmaceutical company Almirall to develop new treatments for severe skin diseases with high level of unmet medical need.